BETA
Your AI-Trained Oncology Knowledge Connection!
Assessing Risk for JAK Inhibitor Selection in Myelofibrosis
In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.
SUNLIGHT Trial Defines CRC in the Refractory Setting
Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.
Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer
Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference.
Exploring New Approaches for ESR1 Mutations in Recent Trials and Future Directions
Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.
Early Data of LEU011 Show Encouraging Potential in Solid Tumors
The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared with hematologic cancers.
Analysis Illuminates CAR T-Cell Optimization for CLL
Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.
Immunotherapy Inches Forward in Head and Neck Cancer Trials
The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.
Promising Trials Expand Approaches Across Multiple Myeloma Settings
John M. Burke, MD, highlights findings from the AQUILA, DREAMM 7, and MajesTEC-5 trials in multiple myeloma.
